The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Abstract
Preamble These recommendations are based on the following: (i) a formal review and analysis of the recently published world literature on the topic (Medline search up to June 2011); (ii) the American College of Physicians' Manual for Assessing Health Practices and Designing Practice Guidelines; (1) (iii) guideline policies of the three societies approving this document; and (iv) the experience of the authors and independent reviewers with regards to non-alcoholic fatty liver disease (NAFLD). Intended for use by physicians and allied health professionals, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible and adjustable for individual patients. Specific recommendations are evidence based wherever possible, and when such evidence is not available or inconsistent, recommendations are made based on the consensus opinion of the authors. To best characterize the evidence cited in support of the recommendations, the AASLD Practice Guidelines Committee has adopted the classification used by the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) workgroup with minor modifications (Table 1) (2). The strength of recommendations in the GRADE system is classified as strong (1) or weak (2). The quality of evidence supporting strong or weak recommendations is designated by one of three levels: high (A), moderate (B), or low quality (C) (2). This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently (3,4,5,6,7,8).Table 1: Grading of recommendations, assessment, development, and evaluation (GRADE)Definitions The definition of NAFLD requires that (i) there is evidence of hepatic steatosis, either by imaging or by histology and (ii) there are no causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of steatogenic medication, or hereditary disorders (Table 2). In the majority of patients, NAFLD is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. NAFLD is histologically further categorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) (Table 3). NAFL is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes. NASH is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis.Table 2: Common causes of secondary hepatic steatosisTable 3: Nonalcoholic fatty liver disease and related definitionsIncidence and prevalence in the general population The incidence of NAFLD has been investigated in a limited number of studies. Two Japanese studies (9,10) reported an incidence rate of 31 and 86 cases of suspected NAFLD per 1,000 person-years, respectively, whereas another study from England showed a much lower incidence rate of 29 cases per 100,000 person-years (11). More studies are needed to better understand the incidence of NAFLD across different age, ethnic, and geographic groups. The reported prevalence of NAFLD varies widely depending on the population studied and the definition used. The prevalence of histologically defined NAFLD was 20 and 51% in two different studies comprised of potential living liver donors (12,13). The reported prevalence of NAFLD when defined by liver ultrasound (US) ranged between 17 and 46% depending on the population studied (4). In a study consisting of nearly 400 middle-aged individuals, the prevalence of NAFLD defined by ultrasonography was 46% and the prevalence of histologically confirmed NASH was 12.2% (14). In the Dallas Heart Study, when assessed by magnetic resonance (MR) spectroscopy, the prevalence of NAFLD in the general population was 31% (15). The prevalence of suspected NAFLD when estimated using aminotransferases alone without imaging or histology ranged between 7 and 11%, but aminotransferases can be normal in individuals with NAFLD (4). In summary, estimates of the worldwide prevalence of NAFLD ranges from 6.3 to 33%, with a median of 20% in the general population, based on a variety of assessment methods (4). On the other hand, the estimated prevalence of NASH is lower, ranging from 3 to 5% (4). The prevalence of NASH cirrhosis in the general population is not known. Prevalence of NAFLD in high-risk groups (Table 4) Obesity is a common and well-documented risk factor for NAFLD. Both excessive body mass index (BMI) and visceral obesity are recognized risk factors for NAFLD. In patients with severe obesity undergoing bariatric surgery, the prevalence of NAFLD can exceed 90% and up to 5% of patients may have unsuspected cirrhosis (4,16,17,18,19,20). There is a very high prevalence of NAFLD in individuals with type 2 diabetes mellitus (T2DM) (4). An ultrasonographic study of patients with T2DM showed a 69% prevalence of NAFLD (
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationAngulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Self-citationNonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationKlein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Telaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Self-citationPrevalence of Fatty Liver in Children and Adolescents
Schwimmer, J. B., Deutsch, R., Kahen, T., Lavine, J. E., Stanley, C., & Behling, C. (2006) · Pediatrics · doi:10.1542/peds.2006-1212 · Cited by 1,481
Self-citationBugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
The prevalence and etiology of elevated aminotransferase levels in the United States
Clark, J. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00265-x · Cited by 1,360
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Lavine, J. E. (2011) · JAMA · doi:10.1001/jama.2011.520 · Cited by 1,101
Self-citationNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease
Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-10-200511150-00009 · Cited by 1,062
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
Söderberg, C., Stål, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., & Hultcrantz, R. (2010) · Hepatology · doi:10.1002/hep.23314 · Cited by 754
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Self-citationResponse-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A. (2011) · Hepatology · doi:10.1002/hep.24376 · Cited by 750
Self-citationHistopathology of Pediatric Nonalcoholic Fatty Liver Disease * #
Schwimmer, J. B., Behling, C., Newbury, R., Deutsch, R., Nievergelt, C., Schork, N. J., & Lavine, J. E. (2005) · Hepatology · doi:10.1002/hep.20842 · Cited by 747
Self-citationRomero-Gómez, M., Del Mar Viloria, M., Andrade, R. J., Salmerón, J., Diago, M., Fernández-Rodríguez, C. M., Corpas, R., Cruz, M., Grande, L., Vázquez, L., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.049 · Cited by 732
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
Harrison, S. A., Torgerson, S., Hayashi, P. H., Ward, J. A., & Schenker, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.005 · Cited by 731
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., & Younossi, Z. M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.005 · Cited by 729
Self-citationUrsodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727 · cited 1×
“Notably, a single large multicenter RCT convincingly showed that UDCA offers no histological benefit over placebo in patients with NASH.(139) Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in humans.”
BackgroundFeldstein, A. E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J. T., Enders, F. B., & Angulo, P. (2009) · Gut · doi:10.1136/gut.2008.171280 · Cited by 726
Bacon, B. R., Adams, P. C., Kowdley, K. V., Powell, L. W., & Tavill, A. S. (2011) · Hepatology · doi:10.1002/hep.24330 · Cited by 723
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Wieckowska, A., Zein, N. N., Yerian, L. M., Lopez, R. A., McCullough, A. J., & Feldstein, A. E. (2006) · Hepatology · doi:10.1002/hep.21223 · Cited by 670
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638
Self-citationJohnson, N. A., Sachinwalla, T., Walton, D. W., Smith, K., Armstrong, A., Thompson, M. W., & George, J. (2009) · Hepatology · doi:10.1002/hep.23129 · Cited by 631
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., & Tanikawa, K. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80287-5 · Cited by 609
Hepatic histology in obese patients undergoing bariatric surgery
Machado, M., Marques-Vidal, P., & Cortez-Pinto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.013 · Cited by 583
Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., Carey, W. D., & the Practice Guidelines Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01481.x · Cited by 569
Self-citationLaurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 566
Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia–Brandt, L., Colloredo, G., Adinolfi, L. E., Asselah, T., Jonsson, J. R., Smedile, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.014 · Cited by 565
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Hepatology · doi:10.1002/hep.23623 · Cited by 564
Vuppalanchi, R., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22603 · Cited by 563
Self-citationLeite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
Sanyal, A. J., Banas, C., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Heuman, D., Coterrell, A., Fisher, R. A., et al. (2006) · Hepatology · doi:10.1002/hep.21103 · Cited by 522
Self-citationEffect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Long term prognosis of fatty liver: risk of chronic liver disease and death
Dam-Larsen, S., Franzmann, M., Andersen, I. B., Christoffersen, P., Jensen, L. B., Sørensen, T. I. A., Becker, U., & Bendtsen, F. (2004) · Gut · doi:10.1136/gut.2003.019984 · Cited by 508
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Cytokines and Nash: A Pilot Study of the Effects of Lifestyle Modification and Vitamin E
Kugelmas, M., Hill, D. B., Vivian, B., Marsano, L., & McClain, C. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50316 · Cited by 504
Larson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504
Caldwell, S. H., & Crespo, D. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.013 · Cited by 501
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., Pigeyre, M., Verkindt, H., Dharancy, S., Louvet, A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.052 · Cited by 483
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470
Self-citationHeritability of Nonalcoholic Fatty Liver Disease
Schwimmer, J. B., Celedon, M. A., Lavine, J. E., Salem, R., Campbell, N., Schork, N. J., Shiehmorteza, M., Yokoo, T., Chavez, A., Middleton, M. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.050 · Cited by 466
Self-citationBhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J. M., Saracco, G., Adams, L. A., Charatcharoenwitthaya, P., Topping, J. H., Bugianesi, E., et al. (2011) · Hepatology · doi:10.1002/hep.24491 · Cited by 450
Huang, M. A., Greenson, J. K., Chao, C., Anderson, L., Peterman, D., Jacobson, J., Emick, D., Lok, A. S., & Conjeevaram, H. S. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41334.x · Cited by 444
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Self-citationDietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440
Sanyal, A. J., Mofrad, P. S., Contos, M. J., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Clore, J., & Mills, A. S. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00457-4 · Cited by 437
Self-citationLong–Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
Hui, J. M., Kench, J. G., Chitturi, S., Sud, A., Farrell, G. C., Byth, K., Hall, P., Khan, M., & George, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50320 · Cited by 437
Hickman, I. J., Jonsson, J. R., Prins, J. B., Ash, S., Purdie, D. M., Clouston, A. D., & Powell, E. E. (2004) · Gut · doi:10.1136/gut.2003.027581 · Cited by 435
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future†
Wieckowska, A., McCullough, A. J., & Feldstein, A. E. (2007) · Hepatology · doi:10.1002/hep.21768 · Cited by 423
Prevalence and risk factors of non‐alcoholic fatty liver disease among Korean adults
PARK, S. H., JEON, W. K., KIM, S. H., KIM, H. J., PARK, D. I., CHO, Y. K., SUNG, I. K., SOHN, C. I., KEUM, D. K., & KIM, B. I. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04086.x · Cited by 422
Willner, I. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03229-4 · Cited by 420
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.023 · Cited by 420
Nobili, V., Manco, M., Devito, R., Di Ciommo, V., Comparcola, D., Sartorelli, M. R., Piemonte, F., Marcellini, M., & Angulo, P. (2008) · Hepatology · doi:10.1002/hep.22336 · Cited by 415
CAPANNI, M., CALELLA, F., BIAGINI, M. R., GENISE, S., RAIMONDI, L., BEDOGNI, G., SVEGLIATI‐BARONI, G., SOFI, F., MILANI, S., ABBATE, R., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02885.x · Cited by 410
Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., & Terano, A. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01083.x · Cited by 408
Hepatic effects of dietary weight loss in morbidly obese subjects
Andersen, T., Gluud, C., Franzmann, M.-B., & Christoffersen, P. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90942-5 · Cited by 407
Metformin in the treatment of patients with non‐alcoholic steatohepatitis
Uygun, A., Kadayifci, A., Isik, A. T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M., & Dagalp, K. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01888.x · Cited by 405
Dietary fat content modifies liver fat in overweight nondiabetic subjects
Westerbacka, J., Lammi, K., Häkkinen, A.-M., Rissanen, A., Salminen, I., Aro, A., & Yki-Järvinen, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1983 · Cited by 379
Prevalence of non-alcoholic fatty liver disease: population based study
Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., Baijal, R., Lala, S., Chaudhary, D., & Deshpande, A. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31922-2 · Cited by 375
Effect of weight reduction on hepatic abnormalities in overweight patients
Palmer, M., & Schaffner, F. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91169-7 · Cited by 374
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369
Self-citationLazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367
Self-citationRatziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Fatty Infiltration of Liver in Hyperlipidemic Patients
Assy, N., Kaita, K., Mymin, D., Levy, C., Rosser, B., & Minuk, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005661516165 · Cited by 360
Dufour, J., Oneta, C. M., Gonvers, J., Bihl, F., Cerny, A., Cereda, J., Zala, J., Helbling, B., Steuerwald, M., & Zimmermann, A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.025 · Cited by 358
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice
Nobili, V., Marcellini, M., Devito, R., Ciampalini, P., Piemonte, F., Comparcola, D., Sartorelli, M. R., & Angulo, P. (2006) · Hepatology · doi:10.1002/hep.21262 · Cited by 352
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Tamura, Y., Tanaka, Y., Sato, F., Choi, J. B., Watada, H., Niwa, M., Kinoshita, J., Ooka, A., Kumashiro, N., Igarashi, Y., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1959 · Cited by 334
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
Dunn, W., Xu, R., Wingard, D. L., Rogers, C., Angulo, P., Younossi, Z. M., & Schwimmer, J. B. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02034.x · Cited by 325
Self-citationMetformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, J. W., Konopski, Z., Eggesbø, H. B., von Volkmann, H. L., Raschpichler, G., Bjøro, K., Haaland, T., Løberg, E. M., & Birkeland, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902845268 · Cited by 323
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
Suzuki, A., Lindor, K., Saver, J. S., Lymp, J., Mendes, F., Muto, A., Okada, T., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.008 · Cited by 319
Yatsuji, S., Hashimoto, E., Tobari, M., Taniai, M., Tokushige, K., & Shiratori, K. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05640.x · Cited by 318
Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.004 · Cited by 317
Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010) · Hepatology · doi:10.1002/hep.23727 · Cited by 317
Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K., & Shiratori, K. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2262-x · Cited by 308
Stepanova, M., Rafiq, N., & Younossi, Z. M. (2010) · Gut · doi:10.1136/gut.2010.213553 · Cited by 303
Self-citationEffect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C
Hickman, I. J., Clouston, A. D., Macdonald, G. A., Purdie, D. M., Prins, J. B., Ash, S., Jonsson, J. R., & Powell, E. E. (2002) · Gut · doi:10.1136/gut.51.1.89 · Cited by 302
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
Struben, V. M. D., Hespenheide, E. E., & Caldwell, S. H. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00315-0 · Cited by 296
Non-Alcoholic Fatty Liver Disease in Older People
Frith, J., Day, C. P., Henderson, E., Burt, A. D., & Newton, J. L. (2009) · Gerontology · doi:10.1159/000235677 · Cited by 282
Dunn, W., Sanyal, A. J., Brunt, E. M., Unalp-Arida, A., Donohue, M., McCullough, A. J., & Schwimmer, J. B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.024 · Cited by 278
Self-citationKantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut · doi:10.1136/gut.2008.151977 · Cited by 273
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.013 · Cited by 272
Lee, J. Y., Kim, K. M., Lee, S. G., Yu, E., Lim, Y.-S., Lee, H. C., Chung, Y.-H., Lee, Y. S., & Suh, D.-J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.007 · Cited by 272
Selection and Outcome of Living Donors for Adult to Adult Right Lobe Transplantation
Marcos, A., Fisher, R. A., Ham, J. M., Olzinski, A. T., Shiffman, M. L., Sanyal, A. J., Luketic, V. A. C., Sterling, R. K., Olbrisch, M. E., & Posner, M. P. (2000) · Transplantation · doi:10.1097/00007890-200006150-00034 · Cited by 272
Self-citationTiikkainen, M., Bergholm, R., Vehkavaara, S., Rissanen, A., Häkkinen, A.-M., Tamminen, M., Teramo, K., & Yki-Järvinen, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.701 · Cited by 271
Nobili, V., Parkes, J., Bottazzo, G., Marcellini, M., Cross, R., Newman, D., Vizzutti, F., Pinzani, M., & Rosenberg, W. M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.013 · Cited by 265
Statins and hepatotoxicity: Focus on patients with fatty liver†
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 265
Self-citationAdvances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 264
Self-citationFoster, T., Budoff, M. J., Saab, S., Ahmadi, N., Gordon, C., & Guerci, A. D. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.299 · Cited by 260
van der Heijden, G., Wang, Z. J., Chu, Z. D., Sauer, P. J. J., Haymond, M. W., Rodriguez, L. M., & Sunehag, A. L. (2010) · Obesity · doi:10.1038/oby.2009.274 · Cited by 253
Athyros, V. G., Mikhailidis, D. P., Didangelos, T. P., Giouleme, O. I., Liberopoulos, E. N., Karagiannis, A., Kakafika, A. I., Tziomalos, K., Burroughs, A. K., & Elisaf, M. S. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104696 · Cited by 248
Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease
Chatrath, H., Vuppalanchi, R., & Chalasani, N. (2012) · Seminars in Liver Disease · doi:10.1055/s-0032-1306423 · Cited by 248
Self-citationLewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007) · Hepatology · doi:10.1002/hep.21848 · Cited by 248
Clinical Correlates of Histopathology in Pediatric Nonalcoholic Steatohepatitis
Patton, H. M., Lavine, J. E., Van Natta, M. L., Schwimmer, J. B., Kleiner, D., & Molleston, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.050 · Cited by 243
Self-citationNelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis
Browning, J. D., Kumar, K. S., Saboorian, M. H., & Thiele, D. L. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04059.x · Cited by 227
BABA, C. S., ALEXANDER, G., KALYANI, B., PANDEY, R., RASTOGI, S., PANDEY, A., & CHOUDHURI, G. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04233.x · Cited by 226
The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study
Tendler, D., Lin, S., Yancy, W. S., Mavropoulos, J., Sylvestre, P., Rockey, D. C., & Westman, E. C. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9433-5 · Cited by 220
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Prashanth, M., Ganesh, H. K., Vima, M. V., John, M., Bandgar, T., Joshi, S., Shah, S., Rathi, P. M., Joshi, A. S., Thakkar, H. U., et al. (2009) · PubMed · Cited by 217
Larson‐Meyer, D. E., Newcomer, B. R., Heilbronn, L. K., Volaufova, J., Smith, S. R., Alfonso, A. J., Lefevre, M., Rood, J. C., Williamson, D. A., Ravussin, E., et al. (2008) · Obesity · doi:10.1038/oby.2008.201 · Cited by 215
Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease
Dunn, W., Xu, R., & Schwimmer, J. B. (2008) · Hepatology · doi:10.1002/hep.22292 · Cited by 213
Shojaee-Moradie, F., Baynes, K. C. R., Pentecost, C., Bell, J. D., Thomas, E. L., Jackson, N. C., Stolinski, M., Whyte, M., Lovell, D., Bowes, S. B., et al. (2007) · Diabetologia · doi:10.1007/s00125-006-0498-7 · Cited by 209
Nonalcoholic Steatohepatitis in Children: A Multicenter Clinicopathological Study†
Carter-Kent, C., Yerian, L. M., Brunt, E. M., Angulo, P., Kohli, R., Ling, S. C., Xanthakos, S. A., Whitington, P. F., Charatcharoenwitthaya, P., Yap, J., et al. (2009) · Hepatology · doi:10.1002/hep.23133 · Cited by 201
Self-citationBeymer, C. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.11.1240 · Cited by 200
Chronological development of elevated aminotransferases in a nonalcoholic population
Suzuki, A., Angulo, P., Lymp, J., St. Sauver, J., Muto, A., Okada, T., & Lindor, K. (2005) · Hepatology · doi:10.1002/hep.20543 · Cited by 197
Magnetic resonance imaging and spectroscopy for monitoring liver steatosis
Cowin, G. J., Jonsson, J. R., Bauer, J. D., Ash, S., Ali, A., Osland, E. J., Purdie, D. M., Clouston, A. D., Powell, E. E., & Galloway, G. J. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21542 · Cited by 191
A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients
GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., & MORENO‐OTERO, R. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02926.x · Cited by 189
Final results of a long-term, clinical follow-up in fatty liver patients
Dam-Larsen, S., Becker, U., Franzmann, M.-B., Larsen, K., Christoffersen, P., & Bendtsen, F. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520903171284 · Cited by 187
Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass
Boza, C., Riquelme, A., Ibañez, L., Duarte, I., Norero, E., Viviani, P., Soza, A., Fernandez, J. I., Raddatz, A., Guzman, S., et al. (2005) · Obesity Surgery · doi:10.1381/0960892055002347 · Cited by 183
Concurrence of Histologic Features of Steatohepatitis with Other Forms of Chronic Liver Disease
Brunt, E. M., Ramrakhiani, S., Cordes, B. G., Neuschwander-Tetri, B. A., Janney, C. G., Bacon, B. R., & Di Bisceglie, A. M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000042420.21088.c7 · Cited by 182
Self-citationKang, H., Greenson, J. K., Omo, J. T., Chao, C., Peterman, D., Anderson, L., Foess-Wood, L., Sherbondy, M. A., & Conjeevaram, H. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00719.x · Cited by 180
Barlow, S. E., & Dietz, W. H. (2002) · Pediatrics · doi:10.1542/peds.110.s1.236 · Cited by 180
MASTERTON, G. S., PLEVRIS, J. N., & HAYES, P. C. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04230.x · Cited by 164
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
Browning, J. D. (2006) · Hepatology · doi:10.1002/hep.21248 · Cited by 162
Is weight reduction an effective therapy for nonalcoholic fatty liver?
Wang, R. T., Koretz, R. L., & Yee, H. F. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00449-2 · Cited by 146
Riley, M. R., Bass, N. M., Rosenthal, P. J., & Merriman, R. B. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.07.020 · Cited by 144
Shields, W., Thompson, K., Grice, G. A., Harrison, S. A., & Coyle, W. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09105462 · Cited by 141
Chen, Z.-W., Chen, L., Dai, H., Chen, J., & Fang, L. (2008) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0720016 · Cited by 140
Chen, C., Huang, M., Yang, J., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04615.x · Cited by 140
Vuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200502000-00002 · Cited by 133
Self-citationIdılman, R., Mızrak, D., CORAPCIOGLU, D., Bektaş, M., Doğanay, B., Saykı, M., Çoban, Ş., Erden, E., Soykan, İ., Emral, R., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03723.x · Cited by 128
High Visceral Fat Mass and High Liver Fat Are Associated with Resistance to Lifestyle Intervention
Thamer, C., Machann, J., Stefan, N., Haap, M. M., Schäfer, S., Brenner, S., Kantartzis, K., Claussen, C. D., Schick, F., Häring, H. U., et al. (2007) · Obesity · doi:10.1038/oby.2007.568 · Cited by 128
Takuma, Y., & Nouso, K. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i12.1436 · Cited by 128
Whalley, S. A., Puvanachandra, P., Desai, A. M., & Kennedy, H. J. (2007) · Clinical Medicine · doi:10.7861/clinmedicine.7-2-119 · Cited by 124
Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort
Wagenknecht, L. E., Scherzinger, A. L., Stamm, E. R., Hanley, A. J., Norris, J. M., Chen, Y. I., Bryer‐Ash, M., Haffner, S. M., & Rotter, J. I. (2009) · Obesity · doi:10.1038/oby.2009.4 · Cited by 121
Effect of Weight Loss on Liver Free Fatty Acid Uptake and Hepatic Insulin Resistance
Viljanen, A. P. M., Iozzo, P., Borra, R., Kankaanpää, M., Karmi, A., Läutamaki, R., Järvisalo, M. J., Parkkola, R. K., Rönnemaa, T., Guiducci, L., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1689 · Cited by 118
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
Omer, Z., Çetinkalp, Ş., Akyıldız, M., Yılmaz, F., Batur, Y., Yılmaz, C., & Akarca, U. S. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832e2baf · Cited by 118
Gunji, T., Matsuhashi, N., Satō, H., Fujibayashi, K., Okumura, M., Sasabe, N., & Urabe, A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.361 · Cited by 113
Moriya, A., Iwasaki, Y., Ohguchi, S., Kayashima, E., Mitsumune, T., Taniguchi, H., Ikeda, F., Shiratori, Y., & Yamamoto, K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04520.x · Cited by 110
Lifestyle intervention in individuals with normal versus impaired glucose tolerance
Schäfer, S., Kantartzis, K., Machann, J., Venter, C., Niess, A. M., Schick, F., Machicao, F. E., Häring, H.-U., Fritsche, A., & Stefan, N. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01820.x · Cited by 108
Meta‐analysis: insulin resistance and sustained virological response in hepatitis C
Eslam, M., Aparcero, R., Kawaguchi, T., Campo, J. A. D., Sata, M., Khattab, M. A., & Romero‐Gómez, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04716.x · Cited by 107
The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease
Hashimoto, E., Yatsuji, S., Kaneda, H., YOSHIOKA, Y., Taniai, M., Tokushige, K., & Shiratori, K. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.09.007 · Cited by 107
Alkhouri, N., Carter-Kent, C. A., López, R., Rosenberg, W. M., Pinzani, M., Bedogni, G., Feldstein, A. E., & Nobili, V. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.015 · Cited by 106
Petta, S., Cammà, C., Marco, V. D., Macaluso, F. S., Maida, M. F., Pizzolanti, G., Belmonte, B., Cabibi, D., Stefano, R. D., Ferraro, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02453.x · Cited by 103
Huynh, H. T., Ngo, V. C., Koong, H. N., Poon, D. Y. H., Choo, S. P., Toh, H. C., Thng, C. H., Chow, P. K. H., Ong, H. S., Chung, A. Y. F., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.008 · Cited by 103
Thomas, E. L., Brynes, A. E., Hamilton, G., Patel, N., Spong, A., Goldin, R. D., Frost, G., Bell, J. D., & Taylor-Robinson, S. D. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i36.5813 · Cited by 102
Ryan, M. C., Wilson, A., Slavin, J., Best, J. D., Jenkins, A. J., & Desmond, P. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1222 · Cited by 100
Duseja, A. K., Das, A., Dhiman, R. K., Chawla, Y. K., Thumburu, K. K., Bhadada, S. K., & Bhansali, A. K. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31902-7 · Cited by 99
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
Antonopoulos, S., Mikros, S., Mylonopoulou, M., Kokkoris, S., & Giannoulis, G. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.021 · Cited by 96
Non-Alcoholic Fatty Liver Disease in Young Adult Severely Obese Non-Diabetic Patients in South Italy
Colicchio, P., Tarantino, G., del Genio, F., Sorrentino, P., Saldalamacchia, G., Finelli, C., Conca, P., Contaldo, F., & Pasanisi, F. (2005) · Annals of Nutrition and Metabolism · doi:10.1159/000087295 · Cited by 93
Nar, A., & Gedik, O. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0067-2 · Cited by 90
Gerss, J., & Köpcke, W. (2009) · PubMed · Cited by 87
Abdelmalek, M. F., Liu, C., Shuster, J. J., Nelson, D. R., & Asal, N. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.001 · Cited by 87
Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China.
Li, H., Wang, Y., Tan, K., Zeng, L., Liu, L., Liu, F., Zhou, T., Chen, E., & Tang, H. W. (2009) · PubMed · Cited by 86
Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality
Berry, D. A., Wathen, J. K., & Newell, M. (2009) · Clinical Trials · doi:10.1177/1740774508101279 · Cited by 82
Cotrim, H. P., de Freitas, L. A., Alves, E. S., de Almeida, A. M., May, D. S., & Caldwell, S. H. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328328f3ec · Cited by 79
Yakaryılmaz, F., Güliter, S., Savaş, B., Erdem, Ö., Ersoy, R., Erden, E., Akyol, G., Bozkaya, H., & Özenirler, S. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01295.x · Cited by 78
Effect of weight control on hepatic abnormalities in obese patients with fatty liver
Park, H. S., Kim, M. W., & Shin, E. S. (1995) · Journal of Korean Medical Science · doi:10.3346/jkms.1995.10.6.414 · Cited by 75
Steatosis and hepatocellular carcinoma risk.
Smedile, A., & Bugianesi, E. (2006) · PubMed · Cited by 71
Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia
Suzuki, A., Angulo, P., Sauver, J. L. S., Muto, A., Okada, T., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01274.x · Cited by 70
Meta‐analysis: antioxidant supplements for liver diseases – the Cochrane Hepato‐Biliary Group
Bjelaković, G., Gluud, L. L., Nikolova, D., Bjelaković, M., Nagorni, A. V., & Gluud, C. N. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04371.x · Cited by 64
Clinical and Histological Features of Nonalcoholic Fatty Liver Disease in Children
Ko, J. S., Yoon, J. M., Yang, H. R., et al. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0949-3 · Cited by 63
Dietrich, M., Jacques, P. F., Pencina, M. J., Lanier, K. J., Keyes, M. J., Jasuja, G. K., Wolf, P. A., D’Agostino, R. B., & Vasan, R. S. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.019 · Cited by 61
Negro, F., & Clément, S. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01186.x · Cited by 61
Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis
Sorrentino, P., Terracciano, L., D’Angelo, S., Ferbo, U., Bracigliano, A., Tarantino, L., Perrella, A., Perrella, O., Chiara, G. D., Panico, L., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0249-x · Cited by 59
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Ethnicity and Nonalcoholic Fatty Liver Disease in an Obesity Clinic: The Impact of Triglycerides
Kallwitz, E. R., Kumar, M., Aggarwal, R., Berger, R., Layden‐Almer, J. E., Gupta, N., & Cotler, S. J. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0234-x · Cited by 50
Haentjens, P., Massaad, D., Reynaert, H., Peeters, E., MEERHAEGHE, A. V., Vinken, S., Poppe, K. G., & Velkeniers, B. (2009) · Acta Clinica Belgica · doi:10.1179/acb.2009.084 · Cited by 42
Bialek, S. R., Redd, J. T., Lynch, A., Vogt, T. M., Lewis, S. K., Wilson, C., & Bell, B. P. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318054492a · Cited by 39
Chronic Liver Disease among Alaska-Native People, 2003–2004
Fischer, G. E., Bialek, S. R., Homan, C., Livingston, S., & McMahon, B. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.57 · Cited by 32
The Role of Iron in Nonalcoholic Fatty Liver Disease: The Story Continues
Kowdley, K. V. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.023 · Cited by 21
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Self-citationNewman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citationPiscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
“Patients were classified as having NAFLD if all other known etiologies of liver disease could be ruled out and if consistent present or past histological or ultrasonographic features of fatty liver and alcohol intake <30 g/day were present.((16)) Fibrosis in NAFLD patients was categorized according to the Kleiner clas…”
Method
Metadata
- Authors
- Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J.
- Venue
- American Journal of Gastroenterology
- Published
- 2012-06
- Volume
- 107
- Issue
- 6
- Pages
- 811-826
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2064085622
- Cited by
- 585
- References
- 189
- FWCI
- 27.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.